Ruoyi Biotech
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese biotech developing novel antibody-based therapies for oncology.
Oncology
Technology Platform
Proprietary antibody engineering platform for developing humanized, bispecific, and antibody-drug conjugate (ADC) therapeutics.
Opportunities
Large and growing oncology market in China, with potential for developing therapies tailored to regional patient needs.
Risk Factors
High clinical development risk and intense competition could challenge differentiation and commercial success.
Competitive Landscape
Operates in the highly competitive global oncology biologics market, facing pressure from large pharma and numerous biotech innovators.